The addition of clopidogrel to aspirin treatment reduces ischemic events in a wide range of
patients with cardiovascular disease. However, recurrent ischemic event occurrence during …

ciation (AHA) convened a writing committee. The ACCF and AHA adhere to a rigorous policy
regarding relationships with industry and other entities (RWI) of authors and peer reviewers …

Context High platelet reactivity while receiving clopidogrel has been linked to cardiovascular
events after percutaneous coronary intervention (PCI), but a treatment strategy for this issue …

Background—The antiplatelet effects of the Platelet Inhibition and Patient Outcomes
(PLATO) trial dose of ticagrelor in patients nonresponsive to clopidogrel and after they …

Intense investigation continues on the pathobiology of stent thrombosis (ST) because of its
morbidity and mortality. Because little advance has been made in outcomes following ST …

Patients with diabetes mellitus have an increased prevalence of vascular disease.
Pathologic thrombosis associated with atherosclerotic plaque rupture is a major cause of …

In the normal course of the delivery of care, anesthesiologists encounter many patients who
are receiving drugs that affect platelet function as a fundamental part of primary and …

P2Y12 inhibitors are widely used in patients with acute coronary syndromes and in the
secondary prevention of thrombotic events in vascular diseases. Within the past few years …

Following an acute coronary syndrome (ACS), heightened predisposition to
atherothrombotic events may persist for years. Advances in understanding the pathobiology …

Objectives: We aimed to test whether cilostazol has beneficial effects in the real-world
patients treated with intracoronary drug-eluting stents (DES). Background: The addition of …